Effects  ||| S:0 E:8 ||| NNS
of  ||| S:8 E:11 ||| IN
Escitalopram  ||| S:11 E:24 ||| NNP
on  ||| S:24 E:27 ||| IN
a  ||| S:27 E:29 ||| DT
Rat  ||| S:29 E:33 ||| NNP
Model  ||| S:33 E:39 ||| NNP
of  ||| S:39 E:42 ||| IN
Persistent  ||| S:42 E:53 ||| NNP
Stress-Altered  ||| S:53 E:68 ||| NNP
Hedonic  ||| S:68 E:76 ||| NNP
Activities ||| S:76 E:86 ||| NNPS
:  ||| S:86 E:88 ||| :
Towards  ||| S:88 E:96 ||| NNP
a  ||| S:96 E:98 ||| DT
New  ||| S:98 E:102 ||| NNP
Understanding  ||| S:102 E:116 ||| NNP
of  ||| S:116 E:119 ||| IN
Stress  ||| S:119 E:126 ||| NNP
and  ||| S:126 E:130 ||| CC
Depression  ||| S:130 E:141 ||| NNP
Chronic  ||| S:141 E:149 ||| NNP
mild  ||| S:149 E:154 ||| JJ
stress  ||| S:154 E:161 ||| NN
( ||| S:161 E:162 ||| -LRB-
CMS ||| S:162 E:165 ||| NNP
)  ||| S:165 E:167 ||| -RRB-
paradigm  ||| S:167 E:176 ||| NN
is  ||| S:176 E:179 ||| VBZ
a  ||| S:179 E:181 ||| DT
model  ||| S:181 E:187 ||| NN
to  ||| S:187 E:190 ||| TO
simulate  ||| S:190 E:199 ||| VB
clinical  ||| S:199 E:208 ||| JJ
depression  ||| S:208 E:219 ||| NN
induced  ||| S:219 E:227 ||| NN
by  ||| S:227 E:230 ||| IN
long-term  ||| S:230 E:240 ||| JJ
environmental  ||| S:240 E:254 ||| JJ
stress ||| S:254 E:260 ||| NN
.  ||| S:260 E:262 ||| .
The  ||| S:262 E:266 ||| DT
present  ||| S:266 E:274 ||| JJ
study  ||| S:274 E:280 ||| NN
investigated  ||| S:280 E:293 ||| VBD
the  ||| S:293 E:297 ||| DT
effects  ||| S:297 E:305 ||| NNS
of  ||| S:305 E:308 ||| IN
escitalopram ||| S:308 E:320 ||| NN
,  ||| S:320 E:322 ||| ,
a  ||| S:322 E:324 ||| DT
specific  ||| S:324 E:333 ||| JJ
serotonin  ||| S:333 E:343 ||| FW
reuptake  ||| S:343 E:352 ||| FW
inhibitor  ||| S:352 E:362 ||| FW
( ||| S:362 E:363 ||| -LRB-
SSRI ||| S:363 E:367 ||| NNP
) ||| S:367 E:368 ||| -RRB-
,  ||| S:368 E:370 ||| ,
on  ||| S:370 E:373 ||| IN
depression-like  ||| S:373 E:389 ||| JJ
activities  ||| S:389 E:400 ||| NNS
in  ||| S:400 E:403 ||| IN
adult  ||| S:403 E:409 ||| NN
( ||| S:409 E:410 ||| -LRB-
18  ||| S:410 E:413 ||| CD
week-old ||| S:413 E:421 ||| NN
)  ||| S:421 E:423 ||| -RRB-
Sprague-Dawley  ||| S:423 E:438 ||| NNP
( ||| S:438 E:439 ||| -LRB-
SD ||| S:439 E:441 ||| NNP
)  ||| S:441 E:443 ||| -RRB-
rats  ||| S:443 E:448 ||| NNS
that  ||| S:448 E:453 ||| WDT
underwent  ||| S:453 E:463 ||| VBD
a  ||| S:463 E:465 ||| DT
total  ||| S:465 E:471 ||| JJ
8-week  ||| S:471 E:478 ||| NNP
CMS ||| S:478 E:481 ||| NNP
.  ||| S:481 E:483 ||| .
Body  ||| S:483 E:488 ||| NN
weight ||| S:488 E:494 ||| NN
,  ||| S:494 E:496 ||| ,
locomotor  ||| S:496 E:506 ||| JJ
activity  ||| S:506 E:515 ||| NN
and  ||| S:515 E:519 ||| CC
sucrose  ||| S:519 E:527 ||| JJ
consumption  ||| S:527 E:539 ||| NN
of  ||| S:539 E:542 ||| IN
the  ||| S:542 E:546 ||| DT
rats  ||| S:546 E:551 ||| NNS
were  ||| S:551 E:556 ||| VBD
measured  ||| S:556 E:565 ||| VBN
under  ||| S:565 E:571 ||| IN
CMS  ||| S:571 E:575 ||| NNP
paradigm  ||| S:575 E:584 ||| NN
and  ||| S:584 E:588 ||| CC
following  ||| S:588 E:598 ||| VBG
escitalopram  ||| S:598 E:611 ||| JJ
treatment ||| S:611 E:620 ||| NN
.  ||| S:620 E:622 ||| .
The  ||| S:622 E:626 ||| DT
plasma  ||| S:626 E:633 ||| JJ
level  ||| S:633 E:639 ||| NN
of  ||| S:639 E:642 ||| IN
corticosterone  ||| S:642 E:657 ||| NN
was  ||| S:657 E:661 ||| VBD
also  ||| S:661 E:666 ||| RB
measured  ||| S:666 E:675 ||| VBN
at  ||| S:675 E:678 ||| IN
the  ||| S:678 E:682 ||| DT
end  ||| S:682 E:686 ||| NN
of  ||| S:686 E:689 ||| IN
the  ||| S:689 E:693 ||| DT
experiment ||| S:693 E:703 ||| NN
.  ||| S:703 E:705 ||| .
Our  ||| S:705 E:709 ||| PRP$
results  ||| S:709 E:717 ||| NNS
revealed  ||| S:717 E:726 ||| VBD
that  ||| S:726 E:731 ||| IN
the  ||| S:731 E:735 ||| DT
CMS  ||| S:735 E:739 ||| NNP
program  ||| S:739 E:747 ||| NN
reduced  ||| S:747 E:755 ||| VBD
the  ||| S:755 E:759 ||| DT
body  ||| S:759 E:764 ||| NN
weight ||| S:764 E:770 ||| NN
,  ||| S:770 E:772 ||| ,
but  ||| S:772 E:776 ||| CC
not  ||| S:776 E:780 ||| RB
the  ||| S:780 E:784 ||| DT
locomotor  ||| S:784 E:794 ||| JJ
activity  ||| S:794 E:803 ||| NN
of  ||| S:803 E:806 ||| IN
the  ||| S:806 E:810 ||| DT
rats ||| S:810 E:814 ||| NNS
.  ||| S:814 E:816 ||| .
Adult  ||| S:816 E:822 ||| NNP
SD  ||| S:822 E:825 ||| NNP
rats  ||| S:825 E:830 ||| NNS
consumed  ||| S:830 E:839 ||| VBN
less  ||| S:839 E:844 ||| RBR
sucrose  ||| S:844 E:852 ||| JJ
solution  ||| S:852 E:861 ||| NN
under  ||| S:861 E:867 ||| IN
CMS ||| S:867 E:870 ||| NNP
.  ||| S:870 E:872 ||| .
However ||| S:872 E:879 ||| RB
,  ||| S:879 E:881 ||| ,
chronic  ||| S:881 E:889 ||| JJ
escitalopram  ||| S:889 E:902 ||| JJ
regime  ||| S:902 E:909 ||| NN
( ||| S:909 E:910 ||| -LRB-
10  ||| S:910 E:913 ||| CD
mg ||| S:913 E:915 ||| CD
/ ||| S:915 E:916 ||| CD
kg ||| S:916 E:918 ||| CD
/ ||| S:918 E:919 ||| CD
day  ||| S:919 E:923 ||| NN
for  ||| S:923 E:927 ||| IN
4  ||| S:927 E:929 ||| CD
weeks ||| S:929 E:934 ||| NNS
)  ||| S:934 E:936 ||| -RRB-
appeared  ||| S:936 E:945 ||| VBD
not  ||| S:945 E:949 ||| RB
helpful  ||| S:949 E:957 ||| JJ
in  ||| S:957 E:960 ||| IN
reversing  ||| S:960 E:970 ||| VBG
this  ||| S:970 E:975 ||| DT
CMS  ||| S:975 E:979 ||| NNP
effect  ||| S:979 E:986 ||| NN
and ||| S:986 E:989 ||| CC
,  ||| S:989 E:991 ||| ,
if  ||| S:991 E:994 ||| IN
any ||| S:994 E:997 ||| DT
,  ||| S:997 E:999 ||| ,
the  ||| S:999 E:1003 ||| DT
drug  ||| S:1003 E:1008 ||| NN
exaggerated  ||| S:1008 E:1020 ||| JJ
anxiety  ||| S:1020 E:1028 ||| NN
profile  ||| S:1028 E:1036 ||| NN
of  ||| S:1036 E:1039 ||| IN
the  ||| S:1039 E:1043 ||| DT
animals ||| S:1043 E:1050 ||| NNS
.  ||| S:1050 E:1052 ||| .
Unexpectedly ||| S:1052 E:1064 ||| RB
,  ||| S:1064 E:1066 ||| ,
the  ||| S:1066 E:1070 ||| DT
stressed  ||| S:1070 E:1079 ||| JJ
rats  ||| S:1079 E:1084 ||| NNS
exhibited  ||| S:1084 E:1094 ||| VBP
higher  ||| S:1094 E:1101 ||| RBR
sucrose  ||| S:1101 E:1109 ||| JJ
consumption  ||| S:1109 E:1121 ||| NN
than  ||| S:1121 E:1126 ||| IN
non-stressed  ||| S:1126 E:1139 ||| JJ
rats  ||| S:1139 E:1144 ||| NNS
after  ||| S:1144 E:1150 ||| IN
receiving  ||| S:1150 E:1160 ||| VBG
repeated  ||| S:1160 E:1169 ||| VBN
saline  ||| S:1169 E:1176 ||| JJ
injections ||| S:1176 E:1186 ||| NNS
.  ||| S:1186 E:1188 ||| .
Further ||| S:1188 E:1195 ||| RB
,  ||| S:1195 E:1197 ||| ,
the  ||| S:1197 E:1201 ||| DT
stressed  ||| S:1201 E:1210 ||| JJ
rats  ||| S:1210 E:1215 ||| NNS
were  ||| S:1215 E:1220 ||| VBD
found  ||| S:1220 E:1226 ||| VBN
to  ||| S:1226 E:1229 ||| TO
have  ||| S:1229 E:1234 ||| VB
a  ||| S:1234 E:1236 ||| DT
higher  ||| S:1236 E:1243 ||| JJR
plasma  ||| S:1243 E:1250 ||| JJ
level  ||| S:1250 E:1256 ||| NN
of  ||| S:1256 E:1259 ||| IN
corticosterone  ||| S:1259 E:1274 ||| NN
after  ||| S:1274 E:1280 ||| IN
escitalopram  ||| S:1280 E:1293 ||| JJ
treatment ||| S:1293 E:1302 ||| NN
.  ||| S:1302 E:1304 ||| .
Our  ||| S:1304 E:1308 ||| PRP$
results  ||| S:1308 E:1316 ||| NNS
provide  ||| S:1316 E:1324 ||| VBP
an  ||| S:1324 E:1327 ||| DT
example  ||| S:1327 E:1335 ||| NN
of  ||| S:1335 E:1338 ||| IN
the  ||| S:1338 E:1342 ||| DT
possibility  ||| S:1342 E:1354 ||| NN
that  ||| S:1354 E:1359 ||| WDT
previously  ||| S:1359 E:1370 ||| RB
stressed  ||| S:1370 E:1379 ||| VBD
individuals  ||| S:1379 E:1391 ||| NNS
may  ||| S:1391 E:1395 ||| MD
develop  ||| S:1395 E:1403 ||| VB
an  ||| S:1403 E:1406 ||| DT
anti-depression  ||| S:1406 E:1422 ||| JJ
ability  ||| S:1422 E:1430 ||| NN
that  ||| S:1430 E:1435 ||| IN
lessens  ||| S:1435 E:1443 ||| VBG
the  ||| S:1443 E:1447 ||| DT
benefits  ||| S:1447 E:1456 ||| NNS
of  ||| S:1456 E:1459 ||| IN
intervention  ||| S:1459 E:1472 ||| NN
with  ||| S:1472 E:1477 ||| IN
antidepressants ||| S:1477 E:1492 ||| NN
.  ||| S:1492 E:1494 ||| .
Finally ||| S:1494 E:1501 ||| RB
,  ||| S:1501 E:1503 ||| ,
a  ||| S:1503 E:1505 ||| DT
separate  ||| S:1505 E:1514 ||| JJ
group  ||| S:1514 E:1520 ||| NN
of  ||| S:1520 E:1523 ||| IN
rats  ||| S:1523 E:1528 ||| NNS
that  ||| S:1528 E:1533 ||| WDT
entered  ||| S:1533 E:1541 ||| VBD
the  ||| S:1541 E:1545 ||| DT
CMS  ||| S:1545 E:1549 ||| NNP
program  ||| S:1549 E:1557 ||| NN
at  ||| S:1557 E:1560 ||| IN
10  ||| S:1560 E:1563 ||| CD
week-old  ||| S:1563 E:1572 ||| NN
were  ||| S:1572 E:1577 ||| VBD
used  ||| S:1577 E:1582 ||| VBN
to  ||| S:1582 E:1585 ||| TO
examine  ||| S:1585 E:1593 ||| VB
possible  ||| S:1593 E:1602 ||| JJ
effects  ||| S:1602 E:1610 ||| NNS
of  ||| S:1610 E:1613 ||| IN
aging  ||| S:1613 E:1619 ||| VBG
to  ||| S:1619 E:1622 ||| TO
interpret  ||| S:1622 E:1632 ||| VB
the  ||| S:1632 E:1636 ||| DT
stress  ||| S:1636 E:1643 ||| NN
coping  ||| S:1643 E:1650 ||| VBG
ability  ||| S:1650 E:1658 ||| NN
observed  ||| S:1658 E:1667 ||| VBD
in  ||| S:1667 E:1670 ||| IN
the  ||| S:1670 E:1674 ||| DT
18  ||| S:1674 E:1677 ||| CD
week-old  ||| S:1677 E:1686 ||| JJ
rats ||| S:1686 E:1690 ||| NNS
.  ||| S:1690 E:1692 ||| .
The  ||| S:1692 E:1696 ||| DT
younger  ||| S:1696 E:1704 ||| JJR
rats  ||| S:1704 E:1709 ||| NNS
developed  ||| S:1709 E:1719 ||| VBD
less  ||| S:1719 E:1724 ||| RBR
anti-anhedonia  ||| S:1724 E:1739 ||| JJ
effects  ||| S:1739 E:1747 ||| NNS
under  ||| S:1747 E:1753 ||| IN
repeated  ||| S:1753 E:1762 ||| VBN
saline  ||| S:1762 E:1769 ||| JJ
injections ||| S:1769 E:1779 ||| NNS
.  ||| S:1779 E:1781 ||| .
The  ||| S:1781 E:1785 ||| DT
data  ||| S:1785 E:1790 ||| NNS
of  ||| S:1790 E:1793 ||| IN
the  ||| S:1793 E:1797 ||| DT
present  ||| S:1797 E:1805 ||| JJ
study  ||| S:1805 E:1811 ||| NN
provide  ||| S:1811 E:1819 ||| VB
a  ||| S:1819 E:1821 ||| DT
different  ||| S:1821 E:1831 ||| JJ
perspective  ||| S:1831 E:1843 ||| NN
on  ||| S:1843 E:1846 ||| IN
stress-induced  ||| S:1846 E:1861 ||| JJ
depression  ||| S:1861 E:1872 ||| NN
and  ||| S:1872 E:1876 ||| CC
possible  ||| S:1876 E:1885 ||| JJ
interaction  ||| S:1885 E:1897 ||| NN
with  ||| S:1897 E:1902 ||| IN
antidepressants ||| S:1902 E:1917 ||| NN
.  ||| S:1917 E:1919 ||| .
